Document Detail

Pharmacokinetic properties and bioavailability of methimazole.
MedLine Citation:
PMID:  4042519     Owner:  NLM     Status:  MEDLINE    
The pharmacokinetics of methimazole following therapeutic doses were studied in healthy subjects, in thyrotoxic and hypothyroid patients before and after treatment to euthyroidism, and in patients with renal or hepatic insufficiency, using a highly sensitive gas chromatographic-mass spectrometric assay. Following intravenous administration of 10mg to healthy subjects, methimazole had an initial distribution half-life (t1/2 alpha) of 0.10 to 0.23 hours and an elimination half-life (t1/2 beta) of 4.9 to 5.7 hours. The absolute bioavailability after oral administration of 10mg methimazole in the fasting state was high, with a mean of 93%. The pharmacokinetic profiles showed small interindividual variations, although one of the hypothyroid patients had a rapid elimination half-life, in both the hypothyroid and euthyroid state (2.6 and 2.4 hours, respectively). The elimination rate was not enhanced in the thyrotoxic patients but was slightly prolonged in the hypothyroid patients. There was no influence of renal insufficiency, but a prolonged elimination half-life was observed in patients with hepatic failure, the prolongation being proportional to the degree of impairment. Thus, the pharmacokinetics of methimazole are relatively simple with small interindividual variations. In general, there are no pharmacokinetic reasons to adjust dosage in the treatment of thyrotoxicosis, except in the rare case of concomitant advanced hepatic insufficiency.
R Jansson; B Lindström; P A Dahlberg
Related Documents :
6416819 - The suppression of tsh in the presence of the normal prl responses to trh out of 26 pat...
16733509 - Work capacity and oxygen uptake abnormalities in hyperthyroidism.
8957489 - Surgical treatment of graves' disease: subtotal or total thyroidectomy?
2281429 - Effects of hypothyroidism on bronchial reactivity in non-asthmatic subjects.
8878129 - Evaluation of external radiation exposure rate from radioiodine-treated hyperthyroid pa...
7057249 - Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidis...
24297689 - High prevalence of occult pulmonary venous hypertension revealed by fluid challenge in ...
15626849 - Vitamin b12 deficiency presenting with an acute reversible extrapyramidal syndrome.
19378719 - Neuroleptic-induced tardive cervical dystonia: clinical series of 20 patients.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Clinical pharmacokinetics     Volume:  10     ISSN:  0312-5963     ISO Abbreviation:  Clin Pharmacokinet     Publication Date:    1985 Sep-Oct
Date Detail:
Created Date:  1985-11-18     Completed Date:  1985-11-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7606849     Medline TA:  Clin Pharmacokinet     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  443-50     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Biological Availability
Debrisoquin / metabolism
Hyperthyroidism / metabolism
Hypothyroidism / metabolism
Methimazole / metabolism*
Middle Aged
Reg. No./Substance:
1131-64-2/Debrisoquin; 60-56-0/Methimazole

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Doxepin plasma concentrations in clinical practice. Could there be a pharmacokinetic explanation for...
Next Document:  Interactions between ethanol and oral contraceptive steroids.